A recent test has created a major advance against HIV, paving the way for a more streamlined prevention option. The existing methods to prevent HIV are centered around the use of daily oral drugs,. Which can be challenging to maintain some individuals. But a study released in the lensate now now indicates that it may be possible to revolutionize HIV prevention with an injection every year. Undevished, HIV explains the immune system through the killing of HIV progressively CD4 cells, leaves the body open to diseases and infections, ultimately proceeds to AIDS, the most advanced phase, where life-threatening diseases occur more often and become more severe.

According to a PTI report, injection is a drug called Lakpavir, developed by the US-based bioframasutical company Gilid Sciences. Lenkapavir prevents HIV from entering and re -introducing human cells, providing long -term protection in a dose of one time. This can be a game-shineer for those who struggle with daily pill management.

Between 18–55 years 40 HIV-negative adults were nominated for phase 1 clinical testing. Two yogas of the drug were tested – one with 5% ethanol and the other with 10%. All subjects received a single intramuscular dose of 5000 mg, and their reaction was monitored by researchers over a period of 56 weeks.

According to the study, the drug was still detected within the body for a period of at least 56 weeks, showing promises for long -term security. In particular, both yogas were safe and well tolerated with minimal side effects.

One of the strongest parts of the test was the safety profile of Lenkapavir. The most frequent side effect information was injection-site pain, which was usually mild and usually lived for about a week. Researchers found that the pre-healing of the area with ice had decreased dramatically discomfort.

Compared to daily oral prep pills, which must be taken hard to work, the administration of the Lenkapavir can simplify the prevention of HIV once a year. This will probably be the most beneficial for members of communities who have limited health care access or have trouble complying with daily pill.

If follow -up tests confirm its safety and effectiveness, the lenkapavir can become a valuable tool in HIV prevention worldwide. An annual injection facility can potentially comprehensive access to preventive therapy and reduce new HIV infections worldwide.

While more research should be done to fully know its long -term effects, optimistic results of this test give hope to treat HIV in future. The future of protection will be a single shot potentially a single shot that will last for a year, which will make it more secure than before.

Now get the latest news with health and braking news and top headlines worldwide.